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Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI)
is effective in many patients, but is not curative and frequently limited by intolerance
or resistance. Also, treatment free remission is a novel option for CML patients and
requires reaching a deep molecular remission, which is not consistently achieved with
TKI monotherapy. Together, multiple unmet clinical needs remain and therefore the
continued need to explore novel treatment strategies. With increasing understanding of
CML biology, many options have been explored and are under investigation. This includes
the use asciminib as first in class inhibitor targeting the myristoyl pocket of BCR-ABL,
combination treatments with established non-TKI drugs such as interferon and drugs with
novel targets relevant to CML biology such as gliptins and thiazolidinediones. Together,
an overview is provided of treatment strategies in development for CML beyond current
TKI monotherapy.
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INTRODUCTION
ChronicMyeloid Leukemia (CML) is a malignant myeloproliferative disease driven by the presence
of the BCR-ABL1 fusion product generated as a result of the t(9;22) Philadelphia chromosome
(Ph). Current treatment revolves around the use of Tyrosine Kinase Inhibitors (TKI) such as
imatinib, which inhibit the oncogenic potential of the BCR-ABL1 protein by blocking its kinase
domain. However, clinical challenges in the treatment of CML persist. Here, we aim to provide
an overview of some new approaches in clinical development for the treatment of CML. We have
limited this overview to chronic phase CML as accelerated and blast phase CML are clinically and
biologically very distinct disease entities.
Prior to the introduction of the TKI imatinib, the main treatment options for CML
included allogeneic stem cell transplantation, chemotherapy such as hydroxyureum or busulphan,
and interferon. With the revolutionizing treatment potential of imatinib, approved by
the FDA and EMA in 2001, the focus since then has been on optimizing the use of
TKI therapy. After imatinib, second and third generation TKIs were developed: bosutinib,
dasatinib, nilotinib, radotinib, and ponatinib. All these compounds target the ATP binding
pocket in the kinase domain of the BCR-ABL oncoprotein, but have a different affinity
in the presence of certain mutations in the kinase domain due to variations in their
chemical structure. This also results in different off-target effects on other tyrosine kinases
and thereby the specific toxicity profile, which is a major clinical factor as approximately
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half of the treatment discontinuations are due to TKI toxicity (1).
Although the great majority of patients with chronic phase CML
have an excellent prognosis, intolerance to currently available
TKI is not uncommon and resistance to TKI therapy due to BCR-
ABL mutations occurs frequently (1). CML-related death due to
progression from chronic to advanced phase disease remains a
reality and ranges up to 15%, depending on clinical factors at
diagnosis as incorporated in e.g., the EUTOS long term survival
score (ELTS) (2, 3).
Although TKI therapy results in a loss of excessive
bone marrow proliferation with effective induction of clinical
remission and prevention of progression to advanced phase
of the disease, the treatment is presumed not to be curative.
Ph+ CML leukemic stem cells are not dependent on BCR-
ABL1 activity for their survival as they reside quiescently
in the bone marrow. Indeed, after prolonged TKI treatment
and clinical disease remission, the BCR-ABL1 fusion product
remains detectable in virtually all CML patients. These low
levels of residual disease are routinely quantified by using Real-
Time Quantitative Polymerase Chain Reaction (RT-qPCR) for
BCR-ABL1 demonstrating so-called deep molecular remissions.
Although continuation of therapy was initially considered
essential, recent studies have shown that ∼50% of patients
in sustained deep molecular remission may stop their TKI
treatment without clinical relapse (4, 5). Importantly, patients
showing loss of a major molecular remission with a BCR-
ABL1 rising above 0.1% on the international scale, universally
regain their major molecular remission upon re-initiation of
their TKI. With close molecular monitoring and timely re-
initiation of TKI therapy, TKI discontinuation has been proven
to be safe in carefully selected patients (4, 5). Since the BCR-
ABL1 fusion product remains detectable in many patients
after TKI discontinuation, this condition is called “Treatment
Free Remission” (TFR), reflecting an operational, but not
true cure. Maintenance of low-levels of residual disease is
supposed to occur through immune regulatory mechanisms
supported by associations of successful TFR with KIR (Killer
Cell Immunoglobulin-like Receptors) haplotypes, T-cell CD62L
expression and CD56 cytotoxic T-cell numbers (4–8). Achieving
TFR is now an important new treatment goal in CML for both
doctors and patients (9). Successful TFR improves quality of life
of patients as they become free of TKI side effects, are no longer
exposed to potential late toxicity and brings substantial drug cost
savings. However, only a minority of patients is eligible to try
Abbreviations: ABL, Abelson tyrosine kinase protein; ALL, Acute Lymphatic
Leukemia; Ara-C, Cytosine Arabinoside; BCR-ABL, Breakpoint Cluster Region—
Abelson fusion product; CITED2, Cbp/p300-Interacting Transactivator
with Glu/Asp-rich carboxy-terminal Domain 2; CML, Chronic Myeloid
Leukemia; CTCAE, Common Terminology Criteria for Adverse Events; DPPIV,
DiPeptidylPeptidase IV; ELTS, EUTOS Long Term Survival Score; EudraCT,
European Union Drug Regulating Authorities Clinical Trials; GIMEMA, Gruppo
Italiano Malattie EMatologiche dell’Adulto (Italian collaborative group for adult
hematological diseases); HHT, Homoharringtonine; HIF, Hypoxia Inducible
Factor; KIR, Killer cell Immunoglobulin-like Receptors; PD-L1, Programmed
death-ligand 1; Ph, Philadelphia Chromosome; PPAR- γ, Peroxisome Proliferator-
Activated Receptor Gamma; RT-qPCR, Real-Time Quantitative Polymerase Chain
Reaction; STAT5, Signal Transducer and Activator of Transcription 5; TFR,
Treatment Free Remission; TKI, Tyrosine Kinase Inhibitor(s).
TABLE 1 | Overview of selected published and ongoing trials investigating
(combination) treatments for chronic phase CML.
Published trials Ongoing trials
TKI/interferon combinations
Bosutinib + pegylated interferon-alpha NCT03831776
Dasatinib + pegylated interferon-alpha Phase II (12)
Imatinib + (pegylated)-interferon-alpha Phase III (13–16)
Nilotinib + pegylated interferon-alpha Phase II (17) NCT01657604
NCT02201459
TKI/chemotherapy combinations
Imatinib + hydroxyurea Phase II (18)
Imatinib + cytarabine Phase III (15, 16, 19)
Imatinib + HHT/omacetaxine Phase II (20)
HHT/omacetaxine alone Phase II (20–22)
Novel TKI inhibitor Asciminib NCT03595917
NCT02081378
NCT03106779
Immune modulation
Dendritic cell vaccinations Phase I/II (23, 24)
Leukemia associated antigen vaccinations Phase I/II (25, 26)
Immune checkpoint inhibitors
Nivolumab + dasatinib NCT02011945
Avelumab + various TKI NCT02767063
PPAR-γ agonists (thiazolidinediones) Phase II (27) NCT02767063
DPPIV inhibitors (gliptins) 2017-000899-28
and discontinue their TKI. In clinical practice, this accumulates
to 31% after 6 years of TKI treatment (1).
New treatment approaches continue to be needed to improve
disease control, avoid the development of TKI resistance and
progression to advanced disease, provide an alternative to current
TKI therapy to mitigate TKI related toxicity, or to improve the
chance of successfully discontinuing therapy to achieve a TFR.
COMBINATION THERAPY WITH TKI FOR
CHRONIC PHASE CML
Preclinical investigations suggest an additive effect of various
classic antineoplastic agents including interferon-alpha,
daunorubicin, etoposide, cytarabine (cytosine arabinoside,
Ara-C), if added to imatinib in vitro (10, 11). Several
of these combinations have also been explored in clinical
studies (Table 1).
TKI + Interferon
Interferon-alpha is effective as monotherapy in patients with
CML and was the treatment of choice over chemotherapy in the
pre-imatinib era (28, 29). Interferon-alpha exerts its antileukemic
effect through a direct anti-proliferative effect specifically on
CML progenitor cells (30, 31) but there may be an additional
immunomodulatory mode of action (32). The clinical trial
leading to the registration of imatinib was the randomized IRIS
trial, which showed marked superiority of imatinib compared
Frontiers in Oncology | www.frontiersin.org 2 August 2019 | Volume 9 | Article 665
Westerweel et al. Novel Treatment Strategies for CML
to interferon in combination with low-dose cytarabine (33). In
the TKI era that followed, interferon monotherapy retained a
limited place in clinical practice, e.g., for patients who were TKI
intolerant or could not be treated with a TKI during pregnancy.
However, because of their different modes of action,
exploration of the potential to combine TKI therapy with
interferon soon followed. Early observations noted dose-
dependent toxicity that limited the use of higher dosages of
interferon cotreatment (34). However, at relatively low dosages,
combination of interferon and imatinib proved better feasible
and resulted in higher rates of cytogenetic and molecular
remission in multiple studies. The Italian GIMEMA study group
showed significantly higher complete cytogenetic remission
(60 vs. 42%, p = 0.003) and major molecular (67 vs. 47%,
p = 0.001) remission rates for imatinib + interferon treated
patients (n = 76) than for patients treated with imatinib alone
(n = 419) at 6 months of treatment. However, at 12 months,
59% of patients had discontinued interferon and this percentage
increased to 87% at 24 months, which may explain the lack
of difference in remission rates after 4 years follow up in the
trial (13). A randomized controlled trial by the Nordic CML
study group found highermajor molecular response rates at 12
months for the combination of interferon and imatinib compared
to imatinib alone (82 vs. 54%, p = 0.002; n = 56 for each
arm), even though 61% of patients discontinued interferon,
mainly due to toxicity. No long term results have been reported
(14). In line with these results, the large French SPIRIT trial
observed significantly higher major molecular response rates
after 12 and 24 months in the interferon-imatinib group than
in the group treated with imatinib alone (57 vs. 38%, p <
0.001 and 64 vs. 43%; p = 0.006, respectively, n = 159 in
each arm). Interestingly, the rate of deep molecular response
(MR4.0) was also higher. Again, the interferon discontinuation
rate was high (83%), mainly due to toxicity, despite a reduction
in the interferon dose during the study (15). Finally, the even
larger German CML IV trial compared imatinib treated patients
(n = 400) with several combinations, including a study arm
in which imatinib was combined with interferon (n = 430).
Consistently, rates and depth of molecular remission were
numerically better when interferon was added to imatinib,
but few patients continued interferon for the long term and
no statistical difference in overall survival was observed (16).
Indeed, none of the aforementioned studies found a statistically
significant reduction in progression to advanced phase disease or
prevention of CML-related death. Taken together, combination
treatment of imatinib with interferon in the upfront setting
therefore does improve the speed and depth of disease remission
on imatinib treatment, but without a benefit on overall survival
and accompanied by significant toxicity resulting in high rates of
interferon discontinuation.
Interferon has also been combined with second generation
TKIs nilotinib (17) and dasatinib (12) in single arm studies with
good efficacy. The combination of nilotinib with peginterferon
alfa-2a at a dose of 90 µg per week, tapered to 45 µg
per week after 1 month treatment was associated with
a substantial incidence of adverse events (17), which is
why a later study used a lower dose (NordDutchCML009
study, ClinicalTrials.gov Identifier: NCT01866553). Dasatinib
combined with even lower doses of peginterferon alfa-2b
(15 µg increasing to 25 µg/week) was well-tolerated (12).
Together, this paved the way for phase III randomized trials
combining second generation TKI with interferon, such as
the German TIGER study comparing nilotinib monotherapy
to a combination of nilotinib with peginterferon alpha-2b
(ClinicalTrials.gov Identifier: NCT01657604) and the French
PETALs study combining nilotinib and peginterferon alpha-
2a (ClinicalTrials.gov Identifier: NCT02201459). No results
have been published for the combination of bosutinib with
interferon, but this is being investigated in the BosuPeg
trial (ClinicalTrials.gov Identifier NCT03831776). The latter
study uses a novel generation of mono-pegylated interferon,
ropeginterferon alfa-2b, which has a longer half-life allowing
biweekly administration and was markedly well-tolerated in
patients with polycythemia vera (35).
A new interest in interferon came when patients previously
treated with interferon were found to retain their molecular
remission after imatinib discontinuation numerically more often
in the STIM and A-STIM French TKI discontinuation trials,
although without achieving statistical significance (36, 37).
In the large Euro-SKI trial that later followed, patients who
used interferon for a substantial period during prior treatment
(>1.5 years), demonstrated a higher chance of durable TKI
discontinuation which was proven to be statistically significant
(38). However, the number of patients in this subgroup was
limited and selection bias may have occurred. Nonetheless,
combination therapy of a TKI with a low dose of interferon for
a limited period of time prior to a TKI discontinuation attempt
could be an interesting option to increase the TFR success rate.
Indeed, such a strategy is a provisional experimental arm in the
French ACTIW study, in which various combination treatments
prior to TKI discontinuation are explored (ClinicalTrials.gov
Identifier: NCT02767063).
Across the interferon trials, the various pegylated forms of
interferon have been most promising, are better tolerated and
more practical for the patient than non-pegylated interferon.
No specific subtype has been proven to be superior as no head
to head comparisons between pegylated interferon variants are
available in the context of CML. A major issue for the future
development of interferon as adjunctive therapy in CML is the
availability of these pegylated interferon formulations because
pharmaceutical companies have recently announced that they
may be discontinuing their production as the primary market,
the treatment of hepatitis C, is diminishing.
TKI + Chemotherapy
Hydroxyurea
Hydroxyurea is a classic chemotherapeutic drug, which was
used to limit leucocyte proliferation before the introduction of
interferon and TKIs. Hydroxyurea is currently still widely used
as temporary treatment to mitigate leukocytosis in de novo CML,
either as short-term monotherapy prior to TKI initiation, e.g.,
while awaiting confirmatory diagnostic testing, or in addition to
TKI therapy to accelerate the rate of cytoreduction. This may
be useful in rare cases of symptomatic hyperleukocytosis, but a
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randomized phase II study showed no benefit of hydroxyurea
as standard additive to imatinib in newly diagnosed patients
for achieving remissions in the course of the disease (18). Also
from preclinical investigations, hydroxyurea was not found to
be synergistic to imatinib and even antagonized some of its
antiproliferative effect (10).
Cytarabine
Adding an intermediate dose cytarabine to imatinib for the
upfront treatment of chronic phase CML proved feasible in
clinical practice (39). Initial studies suggested a beneficial effect
of adding cytarabine to imatinib (40–42). However, no beneficial
effect was observed in later randomized phase III studies, while
it did increase adverse event rates (15, 16, 19). Although some
differences in dosing may explain the discrepant findings, the
addition of low to intermediate doses of cytarabine to TKI in
treatment of chronic phase CML is unlikely to be further pursued.
Homoharringtonine and Omacetaxin
Homoharringtonine (HHT), a plant alkaloid derived from
Cephalotaxus species, and a synthetic formulation of HHT called
omacetaxine, have activity against CML cells through inhibition
of ribosomal protein translation. It is active as monotherapy,
delivered first intravenously followed by twice daily subcutaneous
injections (21, 22). Particularly interesting is the activity of
omacetaxin in CML patients harboring the T315I mutation in
which a complete hematological response was observed in 77%
of the patients, although deep and durable remissions were rare
(43). Omacetaxine is registered in the United States for the
treatment of patients with CML in chronic of accelerated phase
after failure of 2 or more TKIs (44). The EMA application was
not pursued by the company, so it is not available in Europe.
Omacetaxin has been investigated in combination with
imatinib in a small study including CML patients in chronic
phase with TKI resistance or patients with advanced disease, in
which overall response rate was 40% after 4 months (20).
Novel Allosteric BCR-ABL
Inhibitor Asciminib
Apart from the ATP binding pocket in the kinase domain,
the BCR-ABL oncoprotein has a second domain suitable for
pharmacological targeting. This domain is characterized by
a myristoyl binding pocket and serves as an autoinhibitory
site for the wildtype ABL protein. At its N-terminal end,
the ABL protein has a myristoyl group, which binds to
the myristoyl pocket resulting in conformational change and
thereby allosteric “autoinhibition” of kinase activity. In the
BCR-ABL oncoprotein, this myristoyl group is no longer
present as it is lost upon fusion of BCR at the N-terminal
end of ABL. This is why BCR-ABL is constitutively active.
Novel so called allosteric inhibitors targeting this myristoyl
pocket have shown in vitro and in vivo TKI activity (45).
The compound most maturely developed is ABL001, recently
renamed asciminib.
Asciminib is active in inhibiting BCR-ABL positive CML cell
lines and primary hematopoietic cells from CML patients (45).
Its activity is, as would be expected, not influenced by mutations
coding for variations in the ATP binding pocket, including e.g.,
the T315I mutation, known to cause resistance to all currently
available TKIs except ponatinib. Importantly, asciminib has no
activity against non-BCR-ABL harboring cell lines, supporting
the highly selective action against BCR-ABL without off-target
inhibition of other tyrosine kinases. In an animal xenograft
model, asciminib inhibited the expansion of an infused KCL-
22 CML cell line, even after acquiring resistance to the TKI
nilotinib in vivo. However, acquired resistance to asciminib has
also been observed in this model in case mutations occur in
the myristoyl binding site. In this case, sequential treatment
with nilotinib was temporarily effective until a second mutation
occurred in the ATP binding site. Interestingly, no mutational
escape was noted if nilotinib was combined with asciminib and in
fact, the leukemic clone was completely eradicated as combined
treatment could be stopped without recurrence (45). These
promising in vitro observations and in vivo animal experiments
suggest applicability in clinical practice for both monotherapy
and combination therapy.
Asciminib has been tested in a phase I trial for patients with
BCR-ABL positive CML in chronic and advanced phase and in
Ph-positive ALL (ClinicalTrials.gov Identifier: NCT02081378). A
specific cohort was included for patients harboring the T315I
mutation. In this phase I trial, both asciminib monotherapy
and combination therapy with imatinib, dasatinib, and nilotinib
are being investigated. To date, only the results of asciminib
monotherapy in the phase I trial have been publicly presented and
showed significant and durable activity in this patient cohort with
overall good tolerance (46). Toxicity was mostly CTCAE grade
1/2. Observed CTCAEGrade 3/4 toxicity included lipase increase
and hematological toxicity.
Several studies are running to further explore the clinical
potential of asciminib. A phase I trial is investigating a
combination of dasatinib, asciminib, and prednisone for Ph+
ALL or CML in lymphoid blast crisis (ClinicalTrials.gov
Identifier: NCT03595917). A phase II study is investigating
adding asciminib to imatinib in patients with CML treated
with imatinib for at least 2 years who have failed to achieve a
deep molecular remission at the MR4.0 level (ClinicalTrials.gov
Identifier: NCT03578367). Optimizing the molecular response
to MR4.0 or MR4.5 would potentially enable patients to stop
TKI. One phase III trial is running, in which asciminib
monotherapy is randomized against bosutinib for the treatment
of CML patients with resistance or intolerance to at least
two TKIs targeting the kinase domain (ClinicalTrials.gov
identifier NCT03106779). Other studies with asciminib are in
preparation and are likely to impact the treatment of CML in
the future.
ADDITIONAL PATHWAYS
Over the years, much has become clear about the biology of
CML and CML stem cells, which has led to the identification
of many pathways that may be potentially targeted. For a very
comprehensive review see the paper of Massimino et al. (47).
Below, we discuss a selection of the most relevant explorations.
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Immune Modulation
In general, CML is well-known as a disease sensitive to
immunological control, as evidenced by the fact that immune
responses against CML-specific and CML-associated antigens
such as BCR-ABL1, proteinase-3, and WT-1 can be detected in
CML patients (48) and donor lymphocyte infusions are able to
induce long-lasting remissions in relapsed CML patients after
allogeneic SCT (49).
Several small studies have investigated the potential to induce
an anti-leukemic vaccination response in CML patients. A first
strategy is to vaccinate using ex vivo generated autologous
dendritic cells. This has been shown to indeed induce a CML-
specific T-cell response with proliferative capacity after injection
of ex-vivo generated autologous dendritic cells (23, 24). Another
option is to vaccinate patients using leukemia associated antigens.
Injection of BCR-ABL derived peptides was found to be safe and
feasible and indeed induced a T-cell response in the majority
of patients (25, 26). In these single-arm studies, some patients
showed a reduction of cytogenetic and/or molecular depth of
response implying clinical efficacy. But as these were single arm
studies, this cannot be determined with certainty. Prospective
randomized trials are needed, but even though the initial
observations were made more than a decade back, little progress
has been made to move toward randomized controlled phase II
or III trials.
From a theoretical point of view, treatment with
immune checkpoint inhibitors could potentially increase
immunoreactivity against leukemic cells in CML. Indeed,
translational work suggests that PD-L1 upregulation is an
immunological escape mechanism for CML cells (50). Few
clinical observations have been published or presented, but a
phase 1 trial using PD-L1 inhibitor nivolumab in combination
with dasatinib has recently been completed with results pending
(ClinicalTrials.gov Identifier: NCT02011945) and PD-L1
inhibitor avelumab is under investigation for CML patients in
the ACTIW trial (ClinicalTrials.gov Identifier: NCT02767063).
Thiazolidinediones (PPAR-γ Agonists)
Thiazolidinediones are peroxisome proliferator-activated
receptor gamma (PPAR-γ) agonists, which are under
investigation for use as synergizing co-treatment together
with TKI in CML. Thiazolidinediones are already used in
clinical practice for the treatment of diabetes, where they
act as transcription factors that increase tissue sensitivity to
insulin. In vitro, PPAR-γ agonist pioglitazone induced CML
cells to exit quiescence, which in turn sensitizes them to the
effects of imatinib. PPAR-γ agonists serve as transcription
factors that downregulate STAT5 and its targets HIF2α
and CITED2, which are overexpressed in CML stem cells
(51). After promising results in a case series (51) and a
single arm phase 2 study (27), combination treatment of
PPAR-γ agonist pioglitazone with imatinib is now under
prospective randomized investigation (ClinicalTrials.gov
Identifier: NCT02767063).
Gliptins (DPPIV Inhibitors)
By sheer coincidence, another drug class used for the treatment
of diabetes is under investigation for use as co-treatment in CML:
the gliptins. Ph+CD34+ CML cells were found to aberrantly
express dipeptidylpeptidase IV (DPPIV), also known as CD26
(52). Membrane-bound DPPIV is a cleaving protease that
inactivates SDF1, resulting in deregulation of the hematopoietic
niche. DPPIV is not found on hematopoietic CD34+ cells from
patients with other myeloid neoplasms or healthy controls (52).
DPPIV also inactivates various other cytokines such as incretins,
which regulate post-prandial insulin secretion. This is why
DPPIV inhibitors are used for the treatment of diabetes, notably
without causing hypoglycemia in non-diabetic individuals. In
CML, gliptins inhibit aberrantly expressed membrane-bound
DPPIV, thereby restoring the disrupted SDF1 gradient resulting
in normalization of the interaction within the hematopoietic
niche. In anecdotal CML patients with coincidental diabetes,
the initiation of treatment with a gliptin was associated in time
with a deepening of molecular remission (52). A phase 1/2
study combining TKI nilotinib with vildagliptin as pre-treatment
for a TKI discontinuation attempt is currently recruiting
(clinicaltrialsregister.eu. EudraCT: 2017-000899-28).
CONCLUSION
With the introduction of TKI therapy now nearly 20 years ago,
the landscape of CML treatment has fundamentally changed
and the general prognosis of patients presenting in chronic
phase of the disease is excellent. However, TKI therapy is not
curative and long-term exposure to TKI is associated with
chronic side effects, potential health hazards and a financial
burden for health care systems. TKI intolerance is a frequent
clinical problem. Also, some patients develop TKI resistance
resulting in progression to advanced phase and ultimately CML
related death. Treatment free remission is a novel option for CML
patients, but achievable for only a small minority of patients.
Together, multiple unmet clinical needs remain, which clarifies
the continued need to explore novel treatment strategies. With
increasing understanding of CML biology, many options have
been explored. This may include use of the novel class of targeted
BCR-ABL1 inhibitors targeting the myristoyl pocket of BCR-
ABL, combination treatments with established non-TKI drugs
such as interferon or other drugs with novel targets relevant to
CML biology.
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